A citation-based method for searching scientific literature

Nehmat Houssami, Petra Macaskill, Gunter von Minckwitz, Michael L Marinovich, Eleftherios Mamounas. Eur J Cancer 2012
Times Cited: 281







List of co-cited articles
492 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
54

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
43

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
590
21

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
21

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
737
19


Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
15

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
Henry M Kuerer, Gaiane M Rauch, Savitri Krishnamurthy, Beatriz E Adrada, Abigail S Caudle, Sarah M DeSnyder, Dalliah M Black, Lumarie Santiago, Brian P Hobbs, Anthony Lucci,[...]. Ann Surg 2018
95
14

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997
13

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Audree B Tadros, Wei T Yang, Savitri Krishnamurthy, Gaiane M Rauch, Benjamin D Smith, Vicente Valero, Dalliah M Black, Anthony Lucci, Abigail S Caudle, Sarah M DeSnyder,[...]. JAMA Surg 2017
88
14

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Judy C Boughey, Vera J Suman, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, A Marilyn Leitch, Henry M Kuerer, Monet Bowling, Teresa S Flippo-Morton,[...]. JAMA 2013
688
13

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
Jean-Francois Boileau, Brigitte Poirier, Mark Basik, Claire M B Holloway, Louis Gaboury, Lucas Sideris, Sarkis Meterissian, Angel Arnaout, Muriel Brackstone, David R McCready,[...]. J Clin Oncol 2015
352
12

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
12

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
Thorsten Kuehn, Ingo Bauerfeind, Tanja Fehm, Barbara Fleige, Maik Hausschild, Gisela Helms, Annette Lebeau, Cornelia Liedtke, Gunter von Minckwitz, Valentina Nekljudova,[...]. Lancet Oncol 2013
634
12

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Kristine R Broglio, Melanie Quintana, Margaret Foster, Melissa Olinger, Anna McGlothlin, Scott M Berry, Jean-François Boileau, Christine Brezden-Masley, Stephen Chia, Susan Dent,[...]. JAMA Oncol 2016
135
11

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
681
11


Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Sinn,[...]. J Clin Oncol 2017
268
10

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
10


Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Judy C Boughey, Linda M McCall, Karla V Ballman, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, A Marilyn Leitch, Teresa Flippo-Morton, Kelly K Hunt. Ann Surg 2014
215
10

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005
746
10

Response-guided neoadjuvant chemotherapy for breast cancer.
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, Wolfgang Eiermann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2013
202
10

Imaging Neoadjuvant Therapy Response in Breast Cancer.
Amy M Fowler, David A Mankoff, Bonnie N Joe. Radiology 2017
82
10

How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Anita Mamtani, Andrea V Barrio, Tari A King, Kimberly J Van Zee, George Plitas, Melissa Pilewskie, Mahmoud El-Tamer, Mary L Gemignani, Alexandra S Heerdt, Lisa M Sclafani,[...]. Ann Surg Oncol 2016
152
9

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
Bryan T Hennessy, Gabriel N Hortobagyi, Roman Rouzier, Henry Kuerer, Nour Sneige, Aman U Buzdar, Shu Wan Kau, Bruno Fornage, Aysegul Sahin, Kristine Broglio,[...]. J Clin Oncol 2005
279
8

Pathological complete response in neoadjuvant treatment of breast cancer.
Patricia Cortazar, Charles E Geyer. Ann Surg Oncol 2015
117
8

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
822
8


Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Waqar Haque, Vivek Verma, Sandra Hatch, V Suzanne Klimberg, E Brian Butler, Bin S Teh. Breast Cancer Res Treat 2018
83
9

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
526
8

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, M Colleoni, C Denkert, M Piccart-Gebhart, M Regan,[...]. Ann Oncol 2019
258
8

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Laura M Spring, Geoffrey Fell, Andrea Arfe, Chandni Sharma, Rachel Greenup, Kerry L Reynolds, Barbara L Smith, Brian Alexander, Beverly Moy, Steven J Isakoff,[...]. Clin Cancer Res 2020
106
8


Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Abigail S Caudle, Wei T Yang, Savitri Krishnamurthy, Elizabeth A Mittendorf, Dalliah M Black, Michael Z Gilcrease, Isabelle Bedrosian, Brian P Hobbs, Sarah M DeSnyder, Rosa F Hwang,[...]. J Clin Oncol 2016
350
7

Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.
Sarah S Mougalian, Mike Hernandez, Xiudong Lei, Siobhan Lynch, Henry M Kuerer, William F Symmans, Richard L Theriault, Bruno D Fornage, Limin Hsu, Thomas A Buchholz,[...]. JAMA Oncol 2016
71
9

Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.
Brigid K Killelea, Vicky Q Yang, Sarah Mougalian, Nina R Horowitz, Lajos Pusztai, Anees B Chagpar, Donald R Lannin. J Am Coll Surg 2015
90
7

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, J P Julien, M Tubiana-Hulin, C Vandervelden, L Duchateau. J Clin Oncol 2001
737
7

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
517
7

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
297
7

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
779
7

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys. Breast 2003
498
7

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
508
7

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
658
7




Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Laura J Esserman, Donald A Berry, Angela DeMichele, Lisa Carey, Sarah E Davis, Meredith Buxton, Cliff Hudis, Joe W Gray, Charles Perou, Christina Yau,[...]. J Clin Oncol 2012
286
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.